Abstract:INTRODUCTION: Human carbonic anhydrases (EC 4.2.1.1) IX (hCA IX) and XII (hCA XII) are two tumor-associated proteins, being overexpressed in many tumors and involved in critical processes associated with cancer progression and response to therapy. Both are multi-domain proteins consisting of an extracellular catalytic domain (CA), a transmembrane portion (TM) and an intracytoplasmic (IC) segment. These domains have peculiar biochemical and physiological features. CA IX contains an additional proteoglycan-like (PG) domain at the N-terminus which constitutes a unique feature of this enzyme within the CA family.AREAS COVERED: Starting from a brief description of the main molecular and catalytic features of both enzymes, their role in tumor physiology and their three-dimensional structure, this review describes the main classes of small molecule inhibitors, investigated between 2008 and 2013, able to inhibit these enzymes for both diagnostic and therapeutic applications.EXPERT OPINION: A consistent number of patents on molecules able to inhibit the catalytic activity of CA IX and CA XII have been recently reported. Most patents deal with classical sulfonamide derivatives, demonstrating that introducing suitable substituents on the inhibitor scaffold, good selectivity can be obtained. However, the most impressive results are related to compounds containing novel chemotypes, such as coumarins and thiocumarins. Thus, it is expected that research in next future will be more dedicated to the development of molecules containing new chemotypes and a large number of studies in such field have already been published demonstrating the role of these enzymes in carcinogenesis and metastases formation.

Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII

Carbonic anhydrase IX: a new druggable target for the design of antitumor agents

Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target

Inhibition of carbonic anhydrase IX as a novel anticancer mechanism

Synthesis and investigation of selective human carbonic anhydrase IX, XII inhibitors using coumarins bearing a sulfonamide or biotin moiety

Carbonic anhydrase IX inhibitors in cancer therapy: an update

Anticancer carbonic anhydrase inhibitors: a patent review (2008 – 2013)

Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018)

Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one

Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013)

Designing carbonic anhydrase inhibitors for the treatment of breast cancer

Carbonic anhydrase inhibitors: hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX

Privileged Scaffold Hybridization in the Design of Carbonic Anhydrase Inhibitors

Targeting tumor-associated carbonic anhydrase IX in cancer therapy

Recent developments in targeting carbonic anhydrase IX for cancer therapeutics

Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX

Sulfocoumarin-, Coumarin-, 4-Sulfamoylphenyl-Bearing Indazole-3-carboxamide Hybrids: Synthesis and Selective Inhibition of Tumor-Associated Carbonic Anhydrase Isozymes IX and XII

Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX

Synthesis and biological evaluation of new 3-substituted coumarin derivatives as selective inhibitors of human carbonic anhydrase IX and XII

Dual-Tail Approach to Discovery of Novel Carbonic Anhydrase Ix Inhibitors by Simultaneously Matching the Hydrophobic and Hydrophilic Halves of the Active Site

Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment